drugset / Trial / NCT05468645

In Vivo Mass Balance Study of [14C]Hemay005

NCT05468645

Phase 1 Completed 6 enrolled Ganzhou Hemay Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelOther

Summary

This study is a single-center, single-dose, non-randomized, open-label study to evaluate the in vivo mass balance of \[14C\]Hemay005. Six healthy male subjects are planned to be enrolled.

Timeline

Start
2022-07-25
Primary completion
2022-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MUFEMILAST Small molecule 60 mg Oral

Indications

No indication recorded.